{"id":187,"date":"2019-01-29T15:56:38","date_gmt":"2019-01-29T06:56:38","guid":{"rendered":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol-test\/?page_id=187"},"modified":"2022-01-14T13:48:08","modified_gmt":"2022-01-14T04:48:08","slug":"publications2008","status":"publish","type":"page","link":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/publications\/publications2008\/","title":{"rendered":"2008\u5e74\u4ee5\u524d"},"content":{"rendered":"

\u7dcf\u8aac\u30fb\u8457\u66f8\uff08\u65e5\u672c\u8a9e\uff09<\/h4>\n
    \n
  1. \u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u6027\u3001\u8840\u7ba1\u65b0\u751fup-to-date\u3000\u6e0b\u8c37\u6b63\u53f2\u30fb\u4f50\u85e4\u9756\u53f2\u7de8\u300c\u7d30\u80de\u300d\u3001\u30cb\u30e5\u30fc\u30b5\u30a4\u30a8\u30f3\u30b9\u793e\u300140(12)\u300116-19\u30012008<\/li>\n
  2. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u78c1\u6c17\u30d3\u30fc\u30ba\u3092\u7528\u3044\u305f\u304c\u3093\u7d44\u7e54\u304b\u3089\u306e\u7d30\u80de\u5206\u96e2\u6cd5\u3000\u304c\u3093\u8ee2\u79fb\u7814\u7a76\u306e\u5b9f\u9a13\u624b\u6cd5\u3000\u7b2c1\u7248\u3001\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u7de8\u3000\u6e05\u6728\u5143\u6cbb\u30fb\u611b\u7532\u5b5d\u3000\u7de8\u91d1\u82b3\u5802\u3001211-214\u30012008<\/li>\n
  3. \u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u7570\u6027\uff0d\u7406\u60f3\u7684\u306a\u8840\u7ba1\u65b0\u751f\u963b\u5bb3\u5264\u306e\u958b\u767a\u3092\u76ee\u6307\u3057\u3066\u3001\u7dcf\u8aac\u3000\u5b9f\u9a13\u533b\u5b66\u5897\u520a\u53f7\u300c\u6025\u901f\u9032\u5c55\u3059\u308b\u8840\u7ba1\u7814\u7a76\u300d\u3001\u7f8a\u571f\u793e\u300124(18)\u3001152-157\u30012006<\/li>\n<\/ol>\n

    \u548c\u6587\u7dcf\u8aac<\/h4>\n
      \n
    1. Shindoh M, Fujinaga K, Hida K<\/u>, Funaoka K\uff1aPCR application for paraffin-embedded tissues, Tanpakushitsu kakusan koso. Protein, nucleic acid, 41, 463-466, 1996<\/li>\n<\/ol>\n

      \u82f1\u6587\u7dcf\u8aac<\/h4>\n
        \n
      1. *Hida K<\/u>, Hida Y and Shindoh M: Understanding Abnormality of Tumor Endothelial Cells to Develop Ideal Anti-angiogenic Therapies. Cancer Sci<\/em>.<\/strong>\u00a099 (3), 459-466, 2008<\/li>\n
      2. *Hida K<\/u>\u00a0and Klgsbrun M: A new perspective on tumor endothelial cells; Unexpected Chromosome and centrosome abnormalities. Cancer Res,<\/em><\/strong>\u00a065 (7), 1-4, 2005<\/li>\n<\/ol>\n

        \u82f1\u8a9e\u8ad6\u6587<\/h4>\n
          \n
        1. Dudley AC, Shih SC, Cliffe AR, Hida K<\/u> and Klagsbrun M: Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine.\u00a0Br J Cancer<\/em><\/strong>, 99(1), 118-125, 2008.<\/li>\n
        2. Hata H, Kitamura T, Higashino F, Hida K, <\/u>\u00a0Yoshida K, Ohiro Y, Totsuka Y, Kitagawa Y and Shindoh M: Expression of E1AF, and ets-oncogene transcription factor, expression highly correlates with malignant phenotype of malignant melanoma through upregulating membrane-type-1 matrix metalloproteinase gene. Oncol Rep,<\/em><\/strong>\u00a019(5), 1093-1098, 2008<\/li>\n
        3. Amin DN, Hida K,<\/strong><\/u> Bielenberg DR and Klagsbrun M: Expression of epidermal growth factor (EGF) receptor but not ErbB3 in Tumor endothelial cells coincides with responsiveness to EGF and sensitivity to EGFR kinase inhibitors. Cancer Res.,<\/em><\/strong>\u00a066 (4), 2173-2180, 2006<\/li>\n
        4. Kawazoe Y, Kato S, Hida K<\/u>, Shindoh M and Shibata T : Promotion of angiogenesis by inorganic polyphosphate, FASEB J<\/em>,<\/strong>20(5), A1100, 2006<\/li>\n
        5. Hida K<\/u>, Hida Y, Amin D, Flint A, Panigrahy D, Morton C and Klagsbrun M: Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res.,<\/em><\/strong>\u00a064(22), 8249-8255, 2004\u3000\u3014PDF\u3015<\/a><\/li>\n
        6. Kreuter M, Bielenberg D, Hida Y, Hida K<\/u> and Klagsbrun M: Role of neuropilins and semaphorins in angiogenesis and cancer. Ann Hematol<\/em><\/strong>. 2002;81 Suppl 2:S74.<\/li>\n
        7. Shindoh M, Adachi M, Higashino F, Yasuda M, Hida K,<\/strong><\/u> Nishioka K, Takayama S, Reed JC, Imai K, Totsuka Y and Kohgo T: BAG-1 expression correlates highly with the malignant potential in early lesions (T1 and T2) of oral squamous cell carcinoma. Oral Oncol<\/em><\/strong>, 36(5), 444-449, 2000<\/li>\n
        8. Hanzawa M, Shindoh M, Higashino F, Yasuda M, Hida K,<\/strong><\/u> Kohgo T, Nakamura M, Notani K, Totsuka Y, Yoshida K and Fujinaga K: Hepatocyte growth factor upregulates E1AF that induces oral squamous cell carcinoma (SCC) cell invasion by activating matrix metalloproteinase genes. Carcinogenesis<\/em><\/strong>, 21(6), 1079-1085, 2000<\/li>\n
        9. Hida K,<\/strong><\/u> Shindoh M, Yoshida K,\u00a0 Yasuda M, Hanzawa M, Funaoka K, Kohgo T, Amemiya A, Totsuka Y and Fujinaga K: Antisense E1AF transfection restrains oral cancer invasion by reducing MMPs activities. Am J Pathol<\/em><\/strong>, 150, 2125-2132, 1997<\/li>\n
        10. Hida K<\/u>, Shindoh M, Yoshida K, Kudoh A, Funaoka K, Kohgo T, Fujinaga K and Totsuka Y: Expression of E1AF, an ets-family transcription factor, is correlated with the invasive phenotype of oral squamous cell carcinomas. Oral Oncol,<\/em><\/strong>\u00a033(6), 426-430, 1997<\/li>\n
        11. Funaoka K, Shindoh M, Yoshida K, Hanzawa M, Hida K<\/u>, Nishikata S, Totsuka Y and Fijinaga K: Activation of the p21(Waf1\/Cip1) promoter by the ets oncogene family transcription factor E1AF, Biochem Biophys Res Commun<\/em><\/strong>, 236(1), 79-82, 1997<\/li>\n
        12. Shindoh M, Higashino F, Kaya M, Yasuda M, Funaoka K, Hanzawa M, Hida K<\/u>, Kohgo T, Amemiya A, Yoshida K and Fujinaga K: Correlated expression of matrix metalloproteinases and ets-family transcription factor E1A-F in invasive oral-squamous-cell-carcinoma-derived cell lines. Am J Pathol<\/em><\/strong>, 148(3), 693-700, 1996.<\/li>\n<\/ol>\n

          \u62db\u5f85\u8b1b\u6f14<\/h4>\n
            \n
          1. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u65e5\u672c\u751f\u5316\u5b66\u4f1a\u5317\u6d77\u9053\u652f\u90e8\u30fb\u65e5\u672c\u751f\u7269\u7269\u7406\u5b66\u4f1a\u5317\u6d77\u9053\u652f\u90e8\u30fb\u5317\u6d77\u9053\u5206\u5b50\u751f\u7269\u7814\u7a76\u4f1a\uff12\uff10\uff10\uff18\u5e74\u5ea6\u5408\u540c\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u300c\u751f\u547d\u73fe\u8c61\u306e\u5206\u5b50\u30ec\u30d9\u30eb\u3067\u306e\u89e3\u660e\u300d
            \n\u300c\u304c\u3093\u5fae\u5c0f\u74b0\u5883\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7570\u5e38\u6027\u300d\u30012008.11.21\u3001\u5317\u6d77\u9053\u5927\u5b66\u5927\u5b66\u9662\u7406\u5b66\u7814\u7a76\u9662\u5927\u8b1b\u7fa9\u5ba4\uff08\u672d\u5e4c\uff09<\/li>\n
          2. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u91d1\u6ca2\u5927\u5b66\u304c\u3093\u7814\u7a76\u6240\u30bb\u30df\u30ca\u30fc\u3001\u300c\u816b\u760d\u8840\u7ba1\u306e\u591a\u69d8\u6027\uff0d\u7279\u7570\u7684\u306a\u907a\u4f1d\u5b50\u767a\u73fe\u304b\u3089\u67d3\u8272\u4f53\u7570\u5e38\u307e\u3067\uff0d\u300d\u30012008.5.16\uff08\u91d1\u6ca2)<\/li>\n
          3. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u7b2c\uff11\u56de\u6d88\u5316\u5668\u30ea\u30b5\u30fc\u30c1\u30bb\u30df\u30ca\u30fc\u3000\u7279\u5225\u8b1b\u6f14\u300c\u816b\u760d\u8840\u7ba1\u65b0\u751f\u306e\u30c0\u30a4\u30ca\u30df\u30af\u30b9\uff0d\u591a\u69d8\u306a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u6027\uff0d\u300d\u30012008.4.25\uff08\u5e83\u5cf6\uff09<\/li>\n
          4. Hida K<\/u>, Klagsbrun M, Hida Y and Shindoh M:\u00a0 \u201cChromosomal Abnormalities of Human Tumor-Associated Endothelial Cells\u201d THE U.S.-JAPAN COOPERATIVE CANCER RESEARCH PROGRAM WORKSHOP \uff08NCI-JSPS Joint Workshop\uff09\uff1a2008 Mar 19-21\uff1aKyoto Japan<\/li>\n
          5. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a2007\u65e5\u672c\u751f\u5316\u30fb\u5206\u5b50\u751f\u7269\u5b66\u4f1a\u30ef\u30fc\u30af\u30b7\u30e7\u30c3\u30d7 \u201c\u304c\u3093\u5fae\u5c0f\u74b0\u5883\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7570\u5e38\u6027\u201d\u30012007.12.14\uff08\u6a2a\u6d5c\uff09<\/li>\n
          6. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1aBasic Urology Research Seminar \u201d\u304c\u3093\u5fae\u5c0f\u74b0\u5883\u306b\u304a\u3051\u308b\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u7570\u6027 \u7406\u60f3\u7684\u306a\u8840\u7ba1\u65b0\u751f\u963b\u5bb3\u7642\u6cd5\u3092\u958b\u767a\u3059\u308b\u305f\u3081\u306b\u201d\u30012007.8.25\uff08\u767b\u5225\uff09<\/li>\n
          7. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u6625\u671f\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0 \u62db\u5f85\u8b1b\u6f14\u201c\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306b\u95a2\u3059\u308b\u65b0\u3057\u3044\u6d1e\u5bdf\uff0d\u304c\u3093\u5fae\u5c0f\u74b0\u5883\u306b\u304a\u3051\u308b\u8840\u7ba1\u5185\u76ae\u306e\u7279\u7570\u6027\u201c\u30012007.6.30\uff08\u672d\u5e4c\uff09<\/li>\n
          8. Hida K*<\/u>, Klagsbrun M, Hida Y and Shindoh M: Abnormality of tumor endothelial cells. International sessions 2 Cancer Angiogenesis.\u3000The 66th Annual Meeting of the Japanese Cancer Association, 2007.10.3-5 (Yokohama,Japan)<\/li>\n
          9. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u6771\u4eac\u5927\u5b66\u5927\u5b66\u9662\u533b\u5b66\u7cfb\u7814\u7a76\u79d1\u5206\u5b50\u75c5\u7406\u5b66\u8b1b\u5ea7\u30bb\u30df\u30ca\u30fc \u201c\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306b\u95a2\u3059\u308b\u65b0\u3057\u3044\u6d1e\u5bdf\u201d\u30012006.12.15\uff08\u6771\u4eac)<\/li>\n
          10. Hida K<\/u>: The COE 3rd International Symposium\uff5eNovel perspectives in cancer research and translation to the clinic\u201cUnderstanding Abnormality of Tumor Endothelial Cells to Develop Ideal Antiangiogenic Therapies\u201d 2006.11.9\uff08Sendai, Japan\uff09<\/li>\n
          11. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u65ed\u5ddd\u80ba\u764c\u7814\u7a76\u4f1a\u5b66\u8853\u5927\u4f1a\u201c\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306b\u95a2\u3059\u308b\u65b0\u3057\u3044\u6d1e\u5bdf\uff0d\u3088\u308a\u52b9\u679c\u7684\u306a\u8840\u7ba1\u65b0\u751f\u963b\u5bb3\u7642\u6cd5\u3092\u76ee\u6307\u3057\u3066\uff0d\u201d\u30012006.4.28\uff08\u65ed\u5ddd\uff09<\/li>\n
          12. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u5927\u962a\u5927\u5b66\u5927\u5b66\u9662\u533b\u5b66\u7cfb\u7814\u7a76\u79d1\u6a5f\u80fd\u8a3a\u65ad\u79d1\u5b66\u8b1b\u5ea7\u5206\u5b50\u75c5\u7406\u5b66\u6559\u5ba4\u30bb\u30df\u30ca\u30fc\u3001\u201c\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306e\u7570\u5e38\u6027\u201d\u30012005.12.5\uff08\u5927\u962a\uff09<\/li>\n
          13. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u7b2c\uff16\u56de\u611b\u5a9b\u30aa\u30f3\u30b3\u30ed\u30b8\u30fc\u30d5\u30a9\u30fc\u30e9\u30e0\u201d\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306b\u3064\u3044\u3066\u306e\u65b0\u3057\u3044\u6d1e\u5bdf\u201d\u30012005.11.25\uff08\u611b\u5a9b\uff09<\/li>\n
          14. Hida K*<\/u>: AACR Special Conference in Cancer Research \u201cAnti-Angiogenesis and Drug Delivery to tumors:Bench to Bedside and Back\u201d Tumor-associated endothelial cells with cytogenetic abnormalities\u201c 2005.11.9-13 (Boston)<\/li>\n
          15. \u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u5c0f\u6797\u6b63\u4f38\u3001\u9032\u85e4\u6b63\u4fe1\u3001Michael Klagsbrun\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306b\u3064\u3044\u3066\u306e\u65b0\u3057\u3044\u6d1e\u5bdf\u3001\u7b2c85\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u79cb\u671f\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u300c\u8840\u7ba1\u65b0\u751f\u306e\u65b0\u3057\u3044\u30d1\u30e9\u30c0\u30a4\u30e0\u3068\u764c\u300d\u30012005.11.5\uff08\u672d\u5e4c\uff09<\/li>\n
          16. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u7b2c85\u56de\u764c\u8ac7\u8a71\u4f1a \u816b\u760d\u8840\u7ba1\u5185\u76ae\u306b\u3064\u3044\u3066\u306e\u65b0\u3057\u3044\u6d1e\u5bdf\uff0d\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306e\u67d3\u8272\u4f53\u7570\u5e38\u3000\u30df\u30cb\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u30012005.9.3\uff08\u672d\u5e4c\uff09<\/li>\n
          17. Hida K*: <\/u>Boston Angiogenesis Meeting: BAM: \u201cTumor-associated endothelial cells with cytogenetic abnormalities\u201d 2004.11.5 (Boston)<\/li>\n
          18. Hida K*: <\/u>Gordon symposium\uff1a\u201dChromosome instability of Tumor associated Endothelial cells \u201c2004.8.23 (Andover, NH, USA)<\/li>\n
          19. Hida K: <\/u>Tumor Endothelial cells are not normal. Harvard Medical School Surgical Research Spring Seminar\uff1a2003 Apr\uff1aBoston, U.S.A.<\/li>\n
          20. Hida K: <\/u>Characterization of Tumor-deirived Endothelial cells. Harvard Medical School Surgical Research Summer Retreat Seminar\uff1a2002 Jul\uff1aBoston, U.S.A.<\/li>\n<\/ol>\n

            \u56fd\u969b\u5b66\u4f1a\u767a\u8868<\/h4>\n
              \n
            1. Totsuka Y., Kitamura T.,\u00a0Hida K.,<\/strong><\/u>\u00a0Higashino F. and Shindoh M.: Inorganic polyphosphate (poly-P) induces EGF-mediated cell proliferation by activating ERK phosphorylation. The 13th World Congress on Advances in Oncology and 11th International Symposium on Molecular Medicine. 2008.10.9-11, Hersonissos, Crete, Greece<\/li>\n
            2. Shindoh M., Tanaka S., Kitamura T.,\u00a0Hida K*.<\/strong><\/u>, Higashino F. and Totsuka Y.: Pim-1 activates cell motility that induces malignant phenotypes of oral carcinoma. The 13th World Congress on Advances in Oncology and 11th International Symposium on Molecular Medicine. 2008\/10\/9-11 Hersonissos, Crete, Greece<\/li>\n
            3. Hida K<\/u>.\uff1aThe 28th Sapporo International Cancer Symposium \u201cTGF-\u03b2 Signaling and Cancer\u201d, 2008.6.26-27, Sapporo Japan.<\/li>\n
            4. Hida K<\/u>, Klagsbrun M, Hida Y and Shindoh M. \u201cChromosomal Abnormalities of Human Tumor-Associated Endothelial Cells\u201d THE U.S.-JAPAN COOPERATIVE CANCER RESEARCH PROGRAM WORKSHOP \uff08NCI-JSPS Joint Workshop\uff09\uff1a2008 Mar 19-21\uff1aKyoto Japan<\/li>\n
            5. Shindoh M., Higashino F.,\u00a0Hida K*.<\/strong><\/u>\u00a0and Kitamura T.: A novel mechanism of carcinogenesis. Symposiast Oral Cancer Seminar. 120thAnniversary between Thai and Japan Diplomatic Relations Program, 2007.11.29, Bangkok, Thailand<\/li>\n
            6. Hida K*.<\/strong><\/u>, Klagsbrun M., Hida Y. and Shindoh M.: Abnormality of tumor endothelial cells. International sessions 2 Cancer Angiogenesis.The 66th Annual Meeting of the Japanese Cancer Association, 2007.10.3-5\uff08Yokohama, Japan\uff09<\/li>\n
            7. Tsuchiya K.,\u00a0Hida K*.<\/strong><\/u>, Muraki C., Ohga N.<\/strong>, Kondoh T., Miseki T., Shindoh M., Harabayashi T., Shonohara N., Nonomiya K. and Kobayashi M.: Adrenomedullin antagonist inhibits angiogenesis in renal cancer, 98thAnnual Meeting of AACR, 2007.4.13-17, Los Angels<\/li>\n
            8. Muraki C.,\u00a0Hida K*.<\/strong><\/u>, Hida Y., Tsuchiya K., Totsuka Y., Klagasburun M. and Shindoh M.: A cycloocygenase-2 inhibitor suppresses tumou-associated endothelial cell proliferation and migration, 98th Annual Meeting of AACR, 2007.4.13-17, Los Angels<\/li>\n
            9. Hida K*.<\/strong><\/u>, Hida Y., Klagsbrun M. and Shindoh M.: Abnormality of tumor-associated endothelial cells. AACR-JCA International Conference \u201dIn the Forefront of Basic and Translational Cancer Research\u201d 2007.1. 21-25,Waikoloa, Hawaii<\/li>\n
            10. Hida K.<\/strong><\/u>: The COE 3rd International Symposium\uff5eNovel perspectives in cancer research and translation to the clinic\u201cUnderstanding Abnormality of Tumor Endothelial Cells to Develop Ideal Antiangiogenic Therapies\u201d 2006.11.9 (Sendai, Japan)<\/li>\n
            11. Tsuchiya K.,\u00a0Hida K.,<\/strong><\/u>\u00a0Muraki C., Kondoh T., Miseki T., Shindoh M., Harabayashi T., Shinohara N., Nonomura K. and Kobayashi M.: Gene therapy trial for renal cancer in nude mice using an adrenomedullin antagonist, 97th Annual Meeting of AACR, 2006.4.1-5, Washington DC<\/li>\n
            12. Muraki C.,\u00a0Hida K*.<\/strong><\/u>, Hida Y., Shih SC., Tsuchiya K., Kobayashi M., Klagsbrun M. and Shindoh M.: The effect of cyclooxygenase-2 inhibition on tumor-associated endothelial cells. 97th Annual Meeting of AACR, 2006.4.1-5, Washington DC<\/li>\n
            13. Hida K*.<\/strong><\/u>: AACR Special Conference in Cancer Research \u201cAnti-Angiogenesis and Drug Delivery to tumors:Bench to Bedside and Back\u201d Tumor-associated endothelial cells with cytogenetic abnormalities\u201c 2005.11.9-13 (Boston)<\/li>\n
            14. Hida K*.<\/strong><\/u>: Boston Angiogenesis Meeting: BAM: \u201cTumor-associated endothelial cells with cytogenetic abnormalities\u201d 2004.11.5 (Boston)<\/li>\n
            15. Hida K*.<\/strong><\/u>: Gordon symposium\uff1a\u201dChromosome instability of Tumor associated Endothelial cells \u201c2004. 8. 23, Andover, NH, USA<\/li>\n
            16. Hida K*.<\/strong><\/u>: Harvard Medical School Surgical Research Spring Seminar \u201d Tumor Endothelial cells are not normal\u201d 2003.4 (Boston)<\/li>\n
            17. Hida K*.<\/strong><\/u>: Harvard Medical School Surgical Research Summer Retreat Seminar \u201cCharacterization of Tumor-deirived Endothelial cells\u201d 2002.7 (Boston)<\/li>\n<\/ol>\n

              \u56fd\u5185\u5b66\u4f1a\u767a\u8868<\/h4>\n
                \n
              1. \u5927\u8cc0\u5247\u5b5d\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u6751\u6728\u529b\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u677e\u7530\u5149\u5e73\u3001\u5927\u5ee3\u6d0b\u4e00\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u7dd1\u8336\u30dd\u30ea\u30d5\u30a7\u30ce\u30fc\u30eb\u306b\u3088\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3068\u8840\u7ba1\u5185\u76ae\u524d\u99c6\u7d30\u80de\u3078\u306e\u6291\u5236\u52b9\u679c\u3001\u7b2c31\u56de\u65e5\u672c\u5206\u5b50\u751f\u7269\u5b66\u4f1a\u5e74\u4f1a\u3001\u7b2c81\u56de\u65e5\u672c\u751f\u5316\u5b66\u4f1a\u5927\u4f1a\u5408\u540c\u5927\u4f1a\u30012008.12.9-12\uff08\u795e\u6238\uff09<\/li>\n
              2. \u5317\u6751\u54f2\u4e5f\u3001\u7530\u4e2d\u5b97\u4e00\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6771\u91ce\u53f2\u88d5\u3001\u5800\u8d8a\u4fe1\u592b\u3001\u9032\u85e4\u6b63\u4fe1\uff1aDaxx\u306b\u3088\u308bMAP\u30ad\u30ca\u30fc\u30bc\u6d3b\u6027\u5316\u6a5f\u69cb\u3001\u7b2c31\u56de\u65e5\u672c\u5206\u5b50\u751f\u7269\u5b66\u4f1a\u5e74\u4f1a\u3001\u7b2c81\u56de\u65e5\u672c\u751f\u5316\u5b66\u4f1a\u5927\u4f1a\u5408\u540c\u5927\u4f1a\u30012008.12.9-12\uff08\u795e\u6238\uff09<\/li>\n
              3. \u7530\u4e2d\u5b97\u4e00\u3001\u5317\u6751\u54f2\u4e5f\u3001\u6771\u91ce\u53f2\u88d5\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1aPim-1\u306fTRAF2, ASK-1\u3068\u76f8\u4e92\u4f5c\u7528\u3057JNK\u3092\u4e00\u904e\u6027\u306b\u6d3b\u6027\u5316\u3059\u308b\u3001\u7b2c31\u56de\u65e5\u672c\u5206\u5b50\u751f\u7269\u5b66\u4f1a\u5e74\u4f1a\u3001\u7b2c81\u56de\u65e5\u672c\u751f\u5316\u5b66\u4f1a\u5927\u4f1a\u5408\u540c\u5927\u4f1a\u30012008.12.9-12\uff08\u795e\u6238\uff09<\/li>\n
              4. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u65e5\u672c\u751f\u5316\u5b66\u4f1a\u5317\u6d77\u9053\u652f\u90e8\u30fb\u65e5\u672c\u751f\u7269\u7269\u7406\u5b66\u4f1a\u5317\u6d77\u9053\u652f\u90e8\u30fb\u5317\u6d77\u9053\u5206\u5b50\u751f\u7269\u7814\u7a76\u4f1a\uff12\uff10\uff10\uff18\u5e74\u5ea6\u5408\u540c\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u300c\u751f\u547d\u73fe\u8c61\u306e\u5206\u5b50\u30ec\u30d9\u30eb\u3067\u306e\u89e3\u660e\u300d\u300c\u304c\u3093\u5fae\u5c0f\u74b0\u5883\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7570\u5e38\u6027\u300d2008.11.21\u3001\u5317\u6d77\u9053\u5927\u5b66\u5927\u5b66\u9662\u7406\u5b66\u7814\u7a76\u9662\u5927\u8b1b\u7fa9\u5ba4\uff08\u672d\u5e4c\uff09\uff08\u62db\u5f85\u8b1b\u6f14\uff09<\/li>\n
              5. \u5927\u8cc0\u5247\u5b5d\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6751\u6728\u529b\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u7dd1\u8336\u30dd\u30ea\u30d5\u30a7\u30ce\u30fc\u30eb\u306b\u3088\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u524d\u99c6\u7d30\u80de\u3078\u306e\u6291\u5236\u52b9\u679c\u3001\u7b2c67\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012008.10.28-30\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n
              6. \u677e\u7530\u5149\u5e73\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u79cb\u91ce\u6587\u81e3\u3001\u9ed2\u9808\u62d3\u90ce\u3001\u77f3\u5ddd\u4fee\u5e73\u3001\u79cb\u5c71\u5e83\u8f14\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u9577\u671f\u57f9\u990a\u4e0b\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u7570\u6027\u3001\u7b2c88\u56de\u5317\u6d77\u9053\u533b\u5b66\u5927\u4f1a\u75c5\u7406\u5206\u79d1\u4f1a\uff08\u7b2c41\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a\uff09\u30012008.9.20\u3001\u672d\u5e4c\uff08\u5317\u6d77\u9053\u5927\u5b66\u533b\u5b66\u90e8\u81e8\u5e8a\u5927\u8b1b\u5802\uff09<\/li>\n
              7. \u5927\u8cc0\u5247\u5b5d\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u6751\u6728\u529b\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u5927\u5ee3\u6d0b\u4e00\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u7dd1\u8336\u30dd\u30ea\u30d5\u30a7\u30ce\u30fc\u30eb\u306f\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306a\u3089\u3073\u306b\u8840\u7ba1\u5185\u76ae\u524d\u99c6\u7d30\u80de\u306b\u76f4\u63a5\u7684\u306a\u6291\u5236\u52b9\u679c\u3092\u6709\u3059\u308b. \u7b2c88\u56de\u5317\u6d77\u9053\u533b\u5b66\u5927\u4f1a\u816b\u760d\u7cfb\u5206\u79d1\u4f1a\uff08\u7b2c95\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\uff09\u30012008.9.6\u3001\u65ed\u5ddd\uff08\u65ed\u5ddd\u533b\u79d1\u5927\u5b66\uff09<\/li>\n
              8. \u79cb\u91ce\u6587\u81e3\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u677e\u7530\u5149\u5e73\u3001\u9ed2\u9808\u62d3\u90ce\u3001\u77f3\u5ddd\u4fee\u5e73\u3001\u79cb\u5c71\u5e83\u8f14\u3001\u4f50\u6fa4\u967d\u3001\u7be0\u539f\u4fe1\u96c4\u3001\u91ce\u3005\u6751\u514b\u4e5f\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u814e\u764c\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7b2c88\u56de\u5317\u6d77\u9053\u533b\u5b66\u5927\u4f1a\u816b\u760d\u7cfb\u5206\u79d1\u4f1a\uff08\u7b2c95\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\uff09\u30012008.9.6\u3001\u65ed\u5ddd\uff08\u65ed\u5ddd\u533b\u79d1\u5927\u5b66\uff09<\/li>\n
              9. \u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u79cb\u91ce\u6587\u81e3\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u677e\u7530\u5149\u5e73\u3001\u9ed2\u9808\u62d3\u90ce\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6751\u6728\u529b\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u304c\u3093\u5fae\u5c0f\u74b0\u5883\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7570\u5e38\u6027.\u7b2c73\u56de\u65e5\u672c\u30a4\u30f3\u30bf\u30fc\u30d5\u30a7\u30ed\u30f3\u30fb\u30b5\u30a4\u30c8\u30ab\u30a4\u30f3\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u3001\u7b2c19\u56de\u65e5\u672c\u751f\u4f53\u9632\u5fa1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u3001\u7b2c45\u56de\u88dc\u4f53\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u5408\u540c\u5927\u4f1a\u30012008.7.10-12\uff08\u672d\u5e4c\uff09<\/li>\n
              10. \u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u79cb\u91ce\u6587\u81e3\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u677e\u7530\u5149\u5e73\u3001\u9ed2\u9808\u62d3\u90ce\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6751\u6728\u529b\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u304c\u3093\u5fae\u5c0f\u74b0\u5883\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7570\u5e38\u6027. \u65e5\u672c\u5206\u5b50\u751f\u7269\u5b66\u4f1a\u7b2c\uff18\u56de\u6625\u671f\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u30012008.5.25-27\u3001\u672d\u5e4c\uff08\u4eac\u738b\u30d7\u30e9\u30b6\u30db\u30c6\u30eb\u672d\u5e4c\uff09<\/li>\n
              11. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u300c\u816b\u760d\u8840\u7ba1\u306e\u591a\u69d8\u6027\uff0d\u7279\u7570\u7684\u306a\u907a\u4f1d\u5b50\u767a\u73fe\u304b\u3089\u67d3\u8272\u4f53\u7570\u5e38\u307e\u3067\uff0d\u300d\u91d1\u6ca2\u5927\u5b66\u304c\u3093\u7814\u7a76\u6240\u30bb\u30df\u30ca\u30fc\u30012008\u30012008.5.16\u3001\u91d1\u6ca2\uff08\u62db\u5f85\u8b1b\u6f14\uff09<\/li>\n
              12. El-Beialy W., Kitamura T.,\u00a0Hida K.,<\/strong><\/u>, Higashino F., Totsuka Y., Shindoh M.: Enhancing Chemosensitivity of Oral Squamous Carcinomas by Inorganic Poly-Phosphate, \u7b2c97\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012008.5.15-17\uff08\u91d1\u6ca2\uff09<\/li>\n
              13. \u67f3\u5ddd\u5f69\u3001\u5c71\u91ce\u8302\u3001\u6e0b\u8c37\u667a\u548c\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6771\u91ce\u53f2\u88d5\u3001\u6a2a\u5c71\u6566\u90ce\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u30a2\u30c7\u30ce\u30a6\u30a4\u30eb\u30b9\u30b2\u30ce\u30e0\u306b\u304a\u3051\u308b\u30d2\u30b9\u30c8\u30f3\u30bf\u30f3\u30d1\u30af\u306e\u5f79\u5272\u3001\u7b2c97\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012008.5.15-17\uff08\u91d1\u6ca2\uff09<\/li>\n
              14. \u7530\u4e2d\u5b97\u4e00\u3001\u5317\u6751\u54f2\u4e5f\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6771\u91ce\u53f2\u88d5\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u53e3\u8154\u6241\u5e73\u4e0a\u76ae\u304c\u3093\u306b\u304a\u3051\u308bPim-1\u306e\u767a\u73fe\u306f\u7d30\u80de\u904b\u52d5\u80fd\u3092\u4ea2\u9032\u3057\u8ee2\u79fb\u6d3b\u6027\u306b\u95a2\u4e0e\u3059\u308b\u3001\u7b2c97\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012008.5.15-17\uff08\u91d1\u6ca2\uff09<\/li>\n
              15. \u79cb\u91ce\u6587\u81e3\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u6751\u6728\u529b\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u677e\u7530\u5149\u5e73\u3001\u9ed2\u9808\u62d3\u90ce\u3001\u539f\u6797\u900f\u3001\u7be0\u539f\u4fe1\u96c4\u3001\u91ce\u3005\u6751\u514b\u4e5f\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u814e\u764c\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306eaneuploidy\u3001\u7b2c97\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012008.5.15-17\uff08\u91d1\u6ca2\uff09<\/li>\n
              16. \u9ed2\u9808\u62d3\u90ce\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6751\u6728\u529b\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u677e\u7530\u5149\u5e73\u3001\u79cb\u91ce\u6587\u81e3\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u304a\u3051\u308b\u7279\u7570\u30de\u30fc\u30ab\u30fc\u306e\u89e3\u6790\u3000\u7b2c97\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012008.5.15-17\uff08\u91d1\u6ca2\uff09<\/li>\n
              17. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u65b0\u751f\u306e\u30c0\u30a4\u30ca\u30df\u30af\u30b9\uff0d\u591a\u69d8\u306a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u6027\uff0d\u7b2c\uff11\u56de\u6d88\u5316\u5668\u30ea\u30b5\u30fc\u30c1\u30bb\u30df\u30ca\u30fc\u30012008.4.25\u3001\u5e83\u5cf6\u5927\u5b66\uff08\u7279\u5225\u8b1b\u6f14\uff09<\/li>\n
              18. \u79cb\u91ce\u6587\u81e3\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u3001\u6751\u6728\u529b\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u677e\u7530\u5149\u5e73\u3001\u539f\u6797\u900f\u3001\u7be0\u539f\u4fe1\u96c4\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u91ce\u3005\u6751\u514b\u4e5f\uff1a\u814e\u304c\u3093\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7b2c96\u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u7dcf\u4f1a\u30012008.4.25-27\uff08\u6a2a\u6d5c\uff09<\/li>\n
              19. \u5927\u8cc0\u5247\u5b5d\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6751\u6728\u529b\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u7dd1\u8336\u30dd\u30ea\u30d5\u30a7\u30ce\u30fc\u30eb\u306f\u816b\u760d\u8840\u7ba1\u5185 \u76ae\u306a\u3089\u3073\u306b\u8840\u7ba1\u5185\u76ae\u524d\u99c6\u7d30\u80de\u306b\u76f4\u63a5\u7684\u306a\u5236\u5fa1\u52b9\u679c\u3092\u6709\u3059\u308b\u3001\u7b2c15\u56de\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012007.11.29-30\uff08\u798f\u5ca1\uff09<\/li>\n
              20. \u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6751\u6728\u529b\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1aCyclooxygenase-2\u3000inhibitor\u306e\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306a\u3089\u3073\u306b\u8840\u7ba1\u5185\u76ae\u524d\u99c6\u7d30\u80de\u306b\u5bfe\u3059\u308b\u76f4\u63a5\u7684\u5236\u5fa1\u52b9\u679c\u3001\u7b2c15\u56de\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012007.11.29-30\uff08\u798f\u5ca1\uff09<\/li>\n
              21. \u677e\u7530\u5149\u5e73\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6751\u6728\u529b\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u79cb\u91ce\u6587\u81e3\u3001\u9ed2\u9808\u62d3\u90ce\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u5206\u96e2\u57f9\u990a\u3068\u305d\u306e\u7279\u7570\u6027\u3001\u7b2c15\u56de\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012007.11.29-30\uff08\u798f\u5ca1\uff09<\/li>\n
              22. \u79cb\u91ce\u6587\u81e3\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u6751\u6728\u529b\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u677e\u7530\u5149\u5e73\u3001\u9ed2\u9808\u62d3\u90ce\u3001\u3001\u539f\u6797\u900f\u3001\u7be0\u539f\u4fe1\u96c4\u3001\u91ce\u3005\u6751\u514b\u4e5f\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u814e\u764c\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u67d3\u8272\u4f53\u7570\u5e38\u3001\u7b2c15\u56de\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012007.11.29-30\uff08\u798f\u5ca1\uff09<\/li>\n
              23. Akino T.,\u00a0Hida K*.<\/u>, Tsuchiya K., Hida Y., Klagsbrun M., Muraki C., Ohga N., Matsuda K., Harabayashi T., Shinohara N., Nonomura K. and Shindoh M.: Chromosoma abnormalities of tumor endothelial cells in human renal cell carcinoma. \u7b2c66\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012007.10.3-5\uff08\u6a2a\u6d5c\uff09<\/li>\n
              24. Matsuda K.,\u00a0Hida K*.<\/strong><\/u>, Tsuchiya K., Muraki C., Hida Y., Ohga N., Akino T., Totsuka Y., Klagsbrun M. and Shindoh M.: Isolation and characterization of tumor endothelial cells. \u7b2c66\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012007.10.3-5\uff08\u6a2a\u6d5c\uff09<\/li>\n
              25. Muraki C.,\u00a0Hida K*.<\/strong><\/u>, Hida Y., Tsuchiya K., Totsuka Y., Klagsbrun M. and Shindoh M.: Anti-angiobenic effects of cyclooxygenase-2 inhibitor on tumor-associated endothelial cells.\u7b2c66\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012007.10.3-5\uff08\u6a2a\u6d5c\uff09<\/li>\n
              26. Kitamura T.,Hida K*.<\/u>, Higashino F. and Shindoh M.: Phosphorylation of ASK1 stabilizes Daxx and inhibits ist proteasome-dependent degradation.\u7b2c66\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012007.10.3-5\uff08\u6a2a\u6d5c\uff09<\/li>\n
              27. Yanagawa A., Yamano S., Shibuya T., Kitamura T.,\u00a0Hida K*.<\/strong><\/u>, Higashino F, Yokoyama A and Shindoh M.: MicroRNAs can regulate adenovirus gene expression. \u7b2c66\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012007.10.3-5\uff08\u6a2a\u6d5c\uff09<\/li>\n
              28. Ohga N.,\u00a0Hida K*.<\/u>, Muraki C., Hida Y., Tsuchiya K., Totsuka Y. and Shindoh M.: A green tea plyphenol, EGCG has inhibitory effects on tumor endothelial cells and endothelial progenitor cells. \u7b2c66\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012007.10.3-5\uff08\u6a2a\u6d5c\uff09<\/li>\n
              29. \u6a0b\u7530\u4eac\u5b50<\/u>:\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u6625\u671f\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0 \u201c\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306b\u95a2\u3059\u308b\u65b0\u3057\u3044\u6d1e\u5bdf\u30fc\u304c\u3093\u5fae\u5c0f\u74b0\u5883\u306b\u304a\u3051\u308b\u8840\u7ba1\u5185\u76ae\u306e\u7279\u7570\u6027\u30012007.10.3-5. 2007\uff08\u6a2a\u6d5c\uff09<\/li>\n
              30. \u677e\u7530\u5149\u5e73\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6751\u6728\u529b\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u79cb\u91ce\u6587\u81e3\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u5206\u96e2\u306a\u3089\u3073\u306b\u7279\u7570\u6027\u306e\u89e3\u6790\u3001\u7b2c96\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012007.4.19-20\uff08\u5927\u962a\uff09<\/li>\n
              31. \u5c71\u7530\u73e0\u5e0c\u3001\u6d25\u7530\u771f\u5bff\u7f8e\u3001\u5927\u5834\u96c4\u4ecb\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6771\u91ce\u53f2\u88d5\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u4e0a\u76ae\u7d30\u80de\u5897\u6b96\u56e0\u5b50\u53d7\u5bb9\u4f53\u963b\u5bb3\u85ac\uff08EGFR-TKI\uff09\u306b\u3088\u308b\u53e3\u8154\u764c\u7d30\u80de\u306e\u984e\u9aa8\u6d78\u6f64\u6291\u5236\u6a5f\u69cb\u306e\u691c\u8a0e\u3001\u7b2c96\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012007.4.19-20\uff08\u5927\u962a\uff09<\/li>\n
              32. \u5c71\u672c\u6804\u6cbb\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6771\u91ce\u53f2\u88d5\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u30dd\u30ea\u30ea\u30f3\u9178\u306e\u7d30\u80de\u5897\u6b96\u306b\u53ca\u307c\u3059\u5f79\u5272\u3001\u7b2c96\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012007.4.19-20\uff08\u5927\u962a\uff09<\/li>\n
              33. \u5317\u6751\u54f2\u4e5f\u3001\u5927\u5ee3\u6d0b\u4e00\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6771\u91ce\u53f2\u88d5\u3001\u9032\u85e4\u6b63\u4fe1\uff1aaxx\u306b\u3088\u308bMAP\u30ad\u30ca\u30fc\u30bc\u30ab\u30b9\u30b1\u30fc\u30c9\u306e\u6d3b\u6027\u5316\u6a5f\u69cb\u3001\u7b2c96\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012007.4.19-20\uff08\u5927\u962a\uff09<\/li>\n
              34. \u67f3\u5ddd\u3000\u5f69\u3001\u5c71\u91ce\u3000\u8302\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6771\u91ce\u53f2\u88d5\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u30a2\u30c7\u30ce\u30a6\u30a4\u30eb\u30b9\u521d\u671f\u907a\u4f1d\u5b50\u306e\u767a\u73fe\u3092\u6291\u5236\u3059\u308bmiRNA\u3001\u7b2c96\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012007.4.19-20\uff08\u5927\u962a\uff09<\/li>\n
              35. \u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6751\u6728\u3000\u529b\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u677e\u7530\u5149\u5e73\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u7dd1\u8336\u30dd\u30ea\u30d5\u30a7\u30ce\u30fc\u30eb\u306b\u3088\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u3078\u306e\u6291\u5236\u52b9\u679c\u3001\u7b2c65\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012006.9.28-30\uff08\u6a2a\u6d5c\uff09<\/li>\n
              36. \u6751\u6728\u3000\u529b\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1aCyclooxygenase-2 inhibitor\u306f\u816b\u760d\u8840\u7ba1\u65b0\u751f\u3092\u6291\u5236\u3059\u308b\u3001\u7b2c65\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012006.9.28-30\uff08\u6a2a\u6d5c\uff09<\/li>\n
              37. \u571f\u5c4b\u90a6\u5f66\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6751\u6728\u3000\u529b\u3001\u8fd1\u85e4\u3000\u5065\u3001\u4e09\u95a2\u96c5\u7ae0\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u539f\u6797\u3000\u900f\u3001\u7be0\u539f\u4fe1\u96c4\u3001\u91ce\u3005\u6751\u514b\u4e5f\u3001\u5c0f\u6797\u6b63\u4f38\uff1aAdrenomecullin antagonist\u767a\u73fe\u30d9\u30af\u30e9\u30fc\u3092\u7528\u3044\u5c45\u305f\u30d2\u30c8\u814e\u764c\u79fb\u690d\u30de\u30a6\u30b9\u30e2\u30c7\u30eb\u306b\u5bfe\u3059\u308b\u907a\u4f1d\u5b50\u6cbb\u7642\u3001\u7b2c65\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012006.9.28-30\uff08\u6a2a\u6d5c\uff09<\/li>\n
              38. \u6751\u6728\u3000\u529b\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1aCox-2\u963b\u5bb3\u5264\u306b\u3088\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u6291\u5236\u52b9\u679c\u3001\u7b2c60\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u7dcf\u4f1a\u30012006.5.11-12\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n
              39. \u571f\u5c4b\u90a6\u5f66\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6751\u6728\u3000\u529b\u3001\u8fd1\u85e4\u3000\u5065\u3001\u4e09\u95a2\u54f2\u77e2\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u539f\u6797\u3000\u900f\u3001\u7be0\u539f\u4fe1\u96c4\u3001\u91ce\u3005\u6751\u514b\u4e5f\u3001\u5c0f\u6797\u6b63\u4f38\uff1aAdrenomedullin antagonist \u907a\u4f1d\u5b50\u3092\u7528\u3044\u305f\u30de\u30a6\u30b9\u814e\u764c\u30e2\u30c7\u30eb\u306b\u304a\u3051\u308b\u6297\u816b\u760d\u52b9\u679c. \u7b2c95\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012006.4.30-5.2\uff08\u6771\u4eac\uff09<\/li>\n
              40. \u5c0f\u91ce\u5bfa\u96c4\u4e00\u90ce\u3001\u5ddd\u6dfb\u7950\u7f8e\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6771\u91ce\u53f2\u88d5\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u30dd\u30ea\u30ea\u30f3\u9178\u306fRac1\u3092\u4ecb\u3057\u3066\u7d30\u80de\u904b\u52d5\u80fd\u306e\u4ea2\u9032\u3092\u3046\u306a\u304c\u3059\u3001\u7b2c95\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012006.4.30-5.2\uff08\u6771\u4eac\uff09<\/li>\n
              41. \u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6751\u6728\u3000\u529b\u3001\u5c0f\u6797\u6b63\u4f38\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306e\u7279\u7570\u7684\u6027\u8cea \u67d3\u8272\u4f53\u907a\u4f1d\u5b50\u5b66\u7684\u7570\u5e38\u306b\u3064\u3044\u3066\u3001\u7b2c95\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012006.4.30-5.2\uff08\u6771\u4eac\uff09<\/li>\n
              42. \u6751\u6728\u529b\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306b\u304a\u3051\u308bCycloocygenase-2 inhibitor\u306e\u4f5c\u7528\u52b9\u679c\u3001\u7b2c95\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012006.4.30-5.2\uff08\u6771\u4eac\uff09<\/li>\n
              43. \u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u5927\u5ee3\u6d0b\u4e00\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306e\u7279\u7570\u7684\u6027\u8cea \u67d3\u8272\u4f53\u907a\u4f1d\u5b50\u7570\u5e38\u306b\u3064\u3044\u3066\u3001\u7b2c50\u56de\u65e5\u672c\u53e3\u8154\u5916\u79d1\u5b66\u4f1a\u7dcf\u4f1a\u30012005.10.23-25\u3001\u5927\u962a\uff08\u30e1\u30c0\u30eb\u30c6\u30a3\u30b9\u8cde\u53d7\u8cde\uff09<\/li>\n
              44. \u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u816b\u760d\u95a2\u9023\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306f\u7d30\u80de\u767a\u751f\u5b66\u7684\u306b\u7570\u5e38\u3092\u4f34\u3063\u3066\u3044\u308b.\u30ef\u30fc\u30af\u30b7\u30e7\u30c3\u30d7\uff1b\u8840\u7ba1\u65b0\u751f\uff08\uff12\uff09\u3001\u7b2c64\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012005.9.14-16\uff08\u672d\u5e4c\uff09<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

                \u7dcf\u8aac\u30fb\u8457\u66f8\uff08\u65e5\u672c\u8a9e\uff09 \u6a0b\u7530\u4eac\u5b50\u3001\u6a0b\u7530\u6cf0\u6d69\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u6027\u3001\u8840\u7ba1\u65b0\u751fup-to-date\u3000\u6e0b\u8c37\u6b63\u53f2\u30fb\u4f50\u85e4\u9756\u53f2\u7de8\u300c\u7d30\u80de\u300d\u3001\u30cb\u30e5\u30fc\u30b5\u30a4\u30a8\u30f3\u30b9\u793e\u300140(12)\u300116-19\u30012008 \u6a0b\u7530\u4eac\u5b50\uff1a\u78c1\u6c17\u30d3\u30fc\u30ba\u3092\u7528\u3044\u305f\u304c\u3093\u7d44\u7e54\u304b\u3089\u306e\u7d30\u80de\u5206\u96e2\u6cd5\u3000\u304c\u3093\u8ee2\u79fb\u7814\u7a76\u306e\u5b9f\u9a13\u624b\u6cd5\u3000\u7b2c1\u7248\u3001\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u7de8\u3000\u6e05\u6728\u5143\u6cbb\u30fb\u611b\u7532\u5b5d\u3000\u7de8\u91d1\u82b3\u5802\u3001211-214\u30012008 \u6a0b\u7530\u4eac\u5b50\u3001\u6a0b\u7530\u6cf0\u6d69\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u7570\u6027\uff0d\u7406\u60f3\u7684\u306a\u8840\u7ba1…\u7d9a\u304d\u3092\u8aad\u3080<\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"parent":18,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"publications.php","meta":{"footnotes":""},"class_list":["post-187","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages\/187","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/comments?post=187"}],"version-history":[{"count":7,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages\/187\/revisions"}],"predecessor-version":[{"id":433,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages\/187\/revisions\/433"}],"up":[{"embeddable":true,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages\/18"}],"wp:attachment":[{"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/media?parent=187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}